Listen
Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code. Renewal of inclusion on the list of medicines refundable by National Health Insurance.
-
Clinical Benefit
| Substantial |
The actual benefit of LEPONEX in the treatment of schizophrenia remains substantial. The actual benefit of LEPONEX in this indication remains substantial. |
Clinical Added Value
| moderate |
As a second-line therapy, LEPONEX provides a moderate improvement in actual benefit (IAB III) as regards its indication for the treatment of schizophrenia. |
Contact Us
Évaluation des médicaments
